-
Product Insights
New![]()
Net Present Value Model: Foghorn Therapeutics Inc’s FHD-609
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Cardiff Oncology Inc’s Onvansertib Fumarate
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aficamten in Hypertrophic Cardiomyopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aficamten in Hypertrophic Cardiomyopathy Drug Details: Aficamten is under development for the treatment of obstructive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Chronic Myelomonocytic Leukemia (CMML)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.FHD-286 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: FHD-286 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CK-0804 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CK-0804 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:CK-0804 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Myelodysplastic Syndrome Drug Details: FHD-286 is under development for the treatment of relapsed/refractory acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Refractory Acute Myeloid Leukemia Drug Details: FHD-286 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Relapsed Acute Myeloid Leukemia Drug Details: FHD-286 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: FHD-286 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200301 in Soft Tissue Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200301 in Soft Tissue Sarcoma Drug Details:HFB-200301 is under development for the treatment of advanced solid...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.